Libin Philip, PharmD

PARP inhibitors are novel therapies with indication focused on ovarian cancer; however, new agents are being studied for other cancers as well.

It is impossible to assert that patients will not experience any adverse events while on targeted therapy. Communicating and addressing effective mitigation strategies to ameliorate these adverse events can lead to improved clinical outcomes.